CTKBNasdaqLaboratory Analytical InstrumentsFiscal year ends December 31
Cytek Biosciences, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$5.25+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $679.67M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$1.30 (+32.91%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Cytek Biosciences, Inc. grew revenue 5.4% to $206.71M over the twelve months to Jun 30, 2026. Free cash flow was -$12.08M, down 211.1% from a year earlier.
Revenue
$206.71M
+5.4% vs. a year earlier
Operating income
-$44.65M
TTM Q2 2026
Free cash flow
-$12.08M
-211.1% vs. a year earlier
EPS, diluted
-$0.62
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $679.67M
- P/E ratio
- –
- Price to sales
- 3.29
- Price to book
- 2.11
- Dividend yield
- –
- Free cash flow yield
- -1.78%
Fundamentals
- Revenue
- $206.71M
- Net income
- -$66.54M
- EPS, diluted
- -$0.62
- Free cash flow
- -$12.08M
- Book value per share
- $2.49
- Diluted shares
- 129M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
$206.71M+5.4% YoY
Gross profit
$110.03M+3.1% YoY
Operating income
-$44.65M
Net income
–
EPS, diluted
-$0.62
Free cash flow
-$12.08M-211.1% YoY
Reported periodTrailing twelve months